Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
Article Information
vol. 63 no. 9 3091-3103
PubMed
Published By
Print ISSN
Online ISSN
History
- Received November 14, 2013
- Accepted April 10, 2014
- Published in print August 21, 2014.
- Published online ahead of print April 16, 2014.
Article Versions
- Previous version (April 16, 2014 - 08:48).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Author Information
- Sih Min Tan1,
- Arpeeta Sharma1,
- Nada Stefanovic1,
- Derek Y.C. Yuen1,
- Tom C. Karagiannis2,
- Colin Meyer3,
- Keith W. Ward3,
- Mark E. Cooper1 and
- Judy B. de Haan1⇑
- 1Oxidative Stress Laboratory, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
- 2Epigenomic Medicine, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
- 3Reata Pharmaceuticals, Inc., Irving, TX
- Corresponding author: Judy B. de Haan, judy.dehaan{at}bakeridi.edu.au.
Statistics from Altmetric.com
Article usage
In this Issue
September 2014, 63(9)
Derivative of Bardoxolone Methyl, dh404, in an Inverse Dose-Dependent Manner Lessens Diabetes-Associated Atherosclerosis and Improves Diabetic Kidney Disease
